Seres Therapeutics (MCRB) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

MCRB Stock Forecast

Seres Therapeutics stock forecast is as follows: an average price target of $1.25 (represents a 36.54% upside from MCRB’s last price of $0.92) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

MCRB Price Target

The average price target for Seres Therapeutics (MCRB) is $1.25 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $1.25 to $1.25. This represents a potential 36.54% upside from MCRB's last price of $0.92.

MCRB Analyst Ratings

Buy

According to 4 Wall Street analysts, Seres Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for MCRB stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Seres Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 07, 2024	Keay Nakae	Chardan Capital	$1.25	$0.85	46.52%	36.54%

The latest Seres Therapeutics stock forecast, released on Jun 07, 2024 by Keay Nakae from Chardan Capital, set a price target of $1.25, which represents a 46.52% increase from the stock price at the time of the forecast ($0.85), and a 36.54% increase from MCRB last price ($0.92).

Seres Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$1.25
Last Closing Price	$0.92	$0.92	$0.92
Upside/Downside	-100.00%	-100.00%	36.54%

In the current month, the average price target of Seres Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Seres Therapeutics's last price of $0.92. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 12, 2024	Cowen & Co.	Buy	Buy	Hold
Jun 07, 2024	Oppenheimer	Outperform	Perform	Downgrade
May 09, 2024	Oppenheimer	Outperform	Outperform	Hold
Mar 06, 2024	Chardan Capital	Buy	Buy	Hold
Apr 28, 2023	Chardan Capital	Buy	Buy	Hold
Sep 07, 2022	Piper Sandler	Overweight	Overweight	Hold
Jun 08, 2022	Jefferies		Buy	Upgrade

Seres Therapeutics's last stock rating was published by Cowen & Co. on Sep 12, 2024. The company gave MCRB a "Buy" rating, the same as its previous rate.

Seres Therapeutics Financial Forecast

Seres Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	$64.00K	$310.00K	$126.47M	$-522.00K	$975.00K	$3.44M	$1.22M	$1.49M	$7.22M	$126.72M	$5.26M	$5.72M	$17.56M	$1.42M	$6.04M	$8.19M	$7.62M	$7.03M	$12.53M	$7.32M	$3.97M	$3.02M
Avg Forecast	-	$5.88M	$6.25M	$12.50M	$268.67K	$31.00M	$-263.83K	$250.00K	$-155.00K	$1.50M	$125.67M	$1.58M	$6.00M	$7.00M	$4.54M	$8.49M	$12.25M	$28.52M	$5.86M	$6.45M	$6.06M	$7.27M	$9.54M	$8.54M	$6.24M	$6.70M	$8.13M	$15.32M	$4.37M	$3.16M
High Forecast	-	$5.88M	$6.25M	$12.50M	$268.67K	$31.00M	$-263.83K	$250.00K	$-155.00K	$1.50M	$125.67M	$1.58M	$6.00M	$7.00M	$4.54M	$8.49M	$12.25M	$28.52M	$5.86M	$6.45M	$6.06M	$7.27M	$9.54M	$8.54M	$6.24M	$6.70M	$8.13M	$15.32M	$5.25M	$3.79M
Low Forecast	-	$5.88M	$6.25M	$12.50M	$268.67K	$31.00M	$-263.83K	$250.00K	$-155.00K	$1.50M	$125.67M	$1.58M	$6.00M	$7.00M	$4.54M	$8.49M	$12.25M	$28.52M	$5.86M	$6.45M	$6.06M	$7.27M	$9.54M	$8.54M	$6.24M	$6.70M	$8.13M	$15.32M	$3.50M	$2.53M
# Analysts	-	1	1	4	2	6	3	1	3	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	7
Surprise %	-	-	-	-	-	-	-	-	-0.41%	0.21%	1.01%	-0.33%	0.16%	0.49%	0.27%	0.18%	0.59%	4.44%	0.90%	0.89%	2.90%	0.19%	0.63%	0.96%	1.22%	1.05%	1.54%	0.48%	0.91%	0.95%

Seres Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $250.00K, with a low forecast of $250.00K, and a high forecast of $250.00K. MCRB's average Quarter revenue forecast represents a 290.63% increase compared to the company's last Quarter revenue of $64.00K (Dec 23).

Seres Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	-	1	1	4	2	6	3	1	3	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	7
EBITDA	-	-	-	-	-	-	-	-	$-39.96M	$-47.41M	$49.52M	$-67.83M	$-65.29M	$-56.53M	$-61.55M	$-54.14M	$-53.53M	$70.45M	$-46.17M	$-33.29M	$-15.98M	$-27.97M	$-18.30M	$-17.36M	$-16.98M	$-14.53M	$-9.37M	$-21.79M	$-25.98M	$-23.74M
Avg Forecast	-	$-4.78M	$-5.08M	$-10.17M	$-218.57K	$-25.22M	$214.64K	$-203.38K	$126.10K	$-1.22M	$-102.24M	$-1.29M	$-4.88M	$-5.83M	$-3.78M	$-44.77M	$-10.20M	$-23.74M	$-4.87M	$-24.70M	$-5.04M	$-6.05M	$-7.94M	$-17.36M	$-5.20M	$-5.58M	$-6.77M	$-11.68M	$-28.37M	$-24.82M
High Forecast	-	$-4.78M	$-5.08M	$-10.17M	$-218.57K	$-25.22M	$214.64K	$-203.38K	$126.10K	$-1.22M	$-102.24M	$-1.29M	$-4.88M	$-5.83M	$-3.78M	$-35.82M	$-10.20M	$-23.74M	$-4.87M	$-19.76M	$-5.04M	$-6.05M	$-7.94M	$-13.89M	$-5.20M	$-5.58M	$-6.77M	$-9.34M	$-22.70M	$-19.86M
Low Forecast	-	$-4.78M	$-5.08M	$-10.17M	$-218.57K	$-25.22M	$214.64K	$-203.38K	$126.10K	$-1.22M	$-102.24M	$-1.29M	$-4.88M	$-5.83M	$-3.78M	$-53.73M	$-10.20M	$-23.74M	$-4.87M	$-29.64M	$-5.04M	$-6.05M	$-7.94M	$-20.84M	$-5.20M	$-5.58M	$-6.77M	$-14.01M	$-34.04M	$-29.79M
Surprise %	-	-	-	-	-	-	-	-	-316.92%	38.96%	-0.48%	52.70%	13.38%	9.70%	16.28%	1.21%	5.25%	-2.97%	9.47%	1.35%	3.17%	4.62%	2.30%	1.00%	3.27%	2.61%	1.39%	1.87%	0.92%	0.96%

1 analysts predict MCRB's average Quarter EBITDA for Sep 23 to be $-1.22M, with a high of $-1.22M and a low of $-1.22M. This is -102.46% lower than Seres Therapeutics's previous annual EBITDA (Jun 23) of $49.52M.

Seres Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	-	1	1	4	2	6	3	1	3	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	7
Net Income	-	-	-	-	-	-	-	-	$-41.25M	$-47.85M	$46.55M	$-71.78M	$-69.28M	$-60.90M	$-66.14M	$-57.50M	$-44.92M	$68.22M	$-48.33M	$-35.47M	$-18.25M	$-30.28M	$-20.71M	$-19.88M	$-18.78M	$-16.41M	$-10.76M	$-24.33M	$-27.92M	$-25.47M
Avg Forecast	$-26.46M	$-17.94M	$-17.55M	$-12.59M	$-29.97M	$-11.83M	$-41.84M	$-52.16M	$-75.81M	$-76.54M	$81.59M	$-83.96M	$-69.45M	$-71.02M	$-90.34M	$-46.82M	$-66.16M	$-8.25M	$-56.06M	$-26.31M	$-42.42M	$-38.74M	$-39.18M	$-19.88M	$-42.17M	$-48.70M	$-71.78M	$-13.04M	$-30.49M	$-26.63M
High Forecast	$-26.46M	$-17.94M	$-17.55M	$15.74M	$-22.92M	$-11.83M	$-41.84M	$-52.16M	$-62.54M	$-76.54M	$81.59M	$-83.96M	$-69.45M	$-71.02M	$-90.34M	$-37.46M	$-66.16M	$-8.25M	$-56.06M	$-21.05M	$-42.42M	$-38.74M	$-39.18M	$-15.90M	$-42.17M	$-48.70M	$-71.78M	$-10.43M	$-24.39M	$-21.31M
Low Forecast	$-26.46M	$-17.94M	$-17.55M	$-37.78M	$-33.49M	$-11.83M	$-41.84M	$-52.16M	$-92.86M	$-76.54M	$81.59M	$-83.96M	$-69.45M	$-71.02M	$-90.34M	$-56.19M	$-66.16M	$-8.25M	$-56.06M	$-31.58M	$-42.42M	$-38.74M	$-39.18M	$-23.86M	$-42.17M	$-48.70M	$-71.78M	$-15.65M	$-36.59M	$-31.96M
Surprise %	-	-	-	-	-	-	-	-	0.54%	0.63%	0.57%	0.85%	1.00%	0.86%	0.73%	1.23%	0.68%	-8.27%	0.86%	1.35%	0.43%	0.78%	0.53%	1.00%	0.45%	0.34%	0.15%	1.87%	0.92%	0.96%

Seres Therapeutics's average Quarter net income forecast for Sep 23 is $-76.54M, with a range of $-76.54M to $-76.54M. MCRB's average Quarter net income forecast represents a -264.42% decrease compared to the company's last Quarter net income of $46.55M (Jun 23).

Seres Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	-	1	1	4	2	6	3	1	3	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	7
SG&A	-	-	-	-	-	-	-	-	$13.18M	$19.99M	$28.05M	$22.47M	$22.40M	$18.38M	$20.34M	$18.57M	$20.51M	$19.56M	$17.45M	$11.74M	$10.60M	$7.55M	$6.49M	$6.14M	$5.78M	$5.90M	$5.57M	$7.50M	$8.78M	$8.76M
Avg Forecast	-	$16.45M	$17.50M	$34.99M	$752.09K	$86.78M	$-738.56K	$699.83K	$-433.90K	$4.19M	$351.80M	$4.43M	$16.79M	$19.61M	$12.72M	$23.75M	$34.30M	$79.84M	$16.39M	$18.04M	$16.96M	$20.35M	$26.71M	$6.14M	$17.48M	$18.75M	$22.75M	$4.02M	$12.24M	$8.84M
High Forecast	-	$16.45M	$17.50M	$34.99M	$752.09K	$86.78M	$-738.56K	$699.83K	$-433.90K	$4.19M	$351.80M	$4.43M	$16.79M	$19.61M	$12.72M	$23.75M	$34.30M	$79.84M	$16.39M	$18.04M	$16.96M	$20.35M	$26.71M	$7.37M	$17.48M	$18.75M	$22.75M	$4.82M	$14.69M	$10.61M
Low Forecast	-	$16.45M	$17.50M	$34.99M	$752.09K	$86.78M	$-738.56K	$699.83K	$-433.90K	$4.19M	$351.80M	$4.43M	$16.79M	$19.61M	$12.72M	$23.75M	$34.30M	$79.84M	$16.39M	$18.04M	$16.96M	$20.35M	$26.71M	$4.91M	$17.48M	$18.75M	$22.75M	$3.21M	$9.80M	$7.07M
Surprise %	-	-	-	-	-	-	-	-	-30.38%	4.77%	0.08%	5.07%	1.33%	0.94%	1.60%	0.78%	0.60%	0.25%	1.06%	0.65%	0.62%	0.37%	0.24%	1.00%	0.33%	0.31%	0.24%	1.87%	0.72%	0.99%

Seres Therapeutics's average Quarter SG&A projection for Mar 24 is $699.83K, based on 1 Wall Street analysts, with a range of $699.83K to $699.83K. The forecast indicates a -94.69% fall compared to MCRB last annual SG&A of $13.18M (Dec 23).

Seres Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	-	1	1	4	2	6	3	1	3	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	8	8	8	8	10	7
EPS	-	-	-	-	-	-	-	-	$-0.32	$-0.37	-	$-0.57	$-0.64	$-0.50	$-0.72	$-0.62	$-0.49	$0.74	$-0.53	$-0.39	$-0.22	$-0.36	$-0.28	$-0.28	$-0.27	$-0.23	$-0.24	$-0.59	$-0.69	$-0.63
Avg Forecast	$-0.17	$-0.12	$-0.12	$-0.08	$-0.20	$-0.08	$-0.27	$-0.34	$-0.50	$-0.50	$0.53	$-0.55	$-0.46	$-0.47	$-0.60	$-0.52	$-0.44	$-0.05	$-0.37	$-0.31	$-0.28	$-0.26	$-0.26	$-0.28	$-0.28	$-0.32	$-0.47	$-0.40	$-0.83	$-0.69
High Forecast	$-0.17	$-0.12	$-0.12	$0.10	$-0.15	$-0.08	$-0.27	$-0.34	$-0.41	$-0.50	$0.53	$-0.55	$-0.46	$-0.47	$-0.60	$-0.52	$-0.44	$-0.05	$-0.37	$-0.31	$-0.28	$-0.26	$-0.26	$-0.28	$-0.28	$-0.32	$-0.47	$-0.40	$-0.66	$-0.55
Low Forecast	$-0.17	$-0.12	$-0.12	$-0.25	$-0.22	$-0.08	$-0.27	$-0.34	$-0.61	$-0.50	$0.53	$-0.55	$-0.46	$-0.47	$-0.60	$-0.52	$-0.44	$-0.05	$-0.37	$-0.31	$-0.28	$-0.26	$-0.26	$-0.28	$-0.28	$-0.32	$-0.47	$-0.40	$-1.00	$-0.83
Surprise %	-	-	-	-	-	-	-	-	0.64%	0.74%	0.00%	1.04%	1.41%	1.07%	1.21%	1.18%	1.12%	-13.59%	1.43%	1.26%	0.78%	1.41%	1.08%	1.00%	0.95%	0.72%	0.51%	1.49%	0.83%	0.91%

According to 1 Wall Street analysts, Seres Therapeutics's projected average Quarter EPS for Sep 23 is $-0.50, with a low estimate of $-0.50 and a high estimate of $-0.50. This represents a -125457.50% decrease compared to MCRB previous annual EPS of - (Jun 23).

Seres Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
SYRS	Syros Pharmaceuticals	$0.21	$10.00	4661.90%	Buy
FATE	Fate Therapeutics	$1.88	$5.00	165.96%	Buy
IOVA	Iovance Biotherapeutics	$7.81	$12.40	58.77%	Buy
MCRB	Seres Therapeutics	$0.88	$1.25	42.05%	Buy
VCYT	Veracyte	$42.24	$35.00	-17.14%	Buy

MCRB Forecast FAQ

Is Seres Therapeutics a good buy?

Yes, according to 4 Wall Street analysts, Seres Therapeutics (MCRB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of MCRB's total ratings.

What is MCRB's price target?

Seres Therapeutics (MCRB) average price target is $1.25 with a range of $1.25 to $1.25, implying a 36.54% from its last price of $0.915. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Seres Therapeutics stock go up soon?

According to Wall Street analysts' prediction for MCRB stock, the company can go up by 36.54% (from the last price of $0.915 to the average price target of $1.25), up by 36.54% based on the highest stock price target, and up by 36.54% based on the lowest stock price target.

Can Seres Therapeutics stock reach $1?

MCRB's average twelve months analyst stock price target of $1.25 supports the claim that Seres Therapeutics can reach $1 in the near future.

What are Seres Therapeutics's analysts' financial forecasts?

Seres Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $31.25M (high $31.25M, low $31.25M), average EBITDA is $-25.427M (high $-25.427M, low $-25.427M), average net income is $-136M (high $-129M, low $-139M), average SG&A $87.49M (high $87.49M, low $87.49M), and average EPS is $-0.89 (high $-0.843, low $-0.913). MCRB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $24.62M (high $24.62M, low $24.62M), average EBITDA is $-20.033M (high $-20.033M, low $-20.033M), average net income is $-74.543M (high $-46.207M, low $-99.73M), average SG&A $68.93M (high $68.93M, low $68.93M), and average EPS is $-0.488 (high $-0.303, low $-0.653).

Did the MCRB's actual financial results beat the analysts' financial forecasts?

Based on Seres Therapeutics's last annual report (Dec 2023), the company's revenue was $126.32M, which missed the average analysts forecast of $128.59M by -1.76%. Apple's EBITDA was $-108M, beating the average prediction of $-105M by 3.22%. The company's net income was $-114M, missing the average estimation of $-155M by -26.50%. Apple's SG&A was $87.74M, missing the average forecast of $359.98M by -75.63%. Lastly, the company's EPS was $-0.0009, missing the average prediction of $-1.014 by -99.91%. In terms of the last quarterly report (Dec 2023), Seres Therapeutics's revenue was $64K, missing the average analysts' forecast of $-155K by -141.29%. The company's EBITDA was $-39.963M, missing the average prediction of $126.1K by -31792.02%. Seres Therapeutics's net income was $-41.248M, missing the average estimation of $-75.807M by -45.59%. The company's SG&A was $13.18M, missing the average forecast of $-434K by -3137.82%. Lastly, the company's EPS was $-0.32, missing the average prediction of $-0.497 by -35.56%